Avid Bioservices - Stock Price History | CDMO

Historical daily share price chart and data for Avid Bioservices since 2021 adjusted for splits. The latest closing stock price for Avid Bioservices as of October 15, 2021 is 25.79.
  • The all-time high Avid Bioservices stock closing price was 28.32 on August 10, 2021.
  • The Avid Bioservices 52-week high stock price is 28.36, which is 10% above the current share price.
  • The Avid Bioservices 52-week low stock price is 6.99, which is 72.9% below the current share price.
  • The average Avid Bioservices stock price for the last 52 weeks is 18.54.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Avid Bioservices Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 7.1012 7.3900 11.7600 3.1500 11.5400 50.46%
2019 5.0766 4.2700 8.1600 3.4300 7.6700 87.07%
2018 4.4375 4.1050 7.3200 2.3200 4.1000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.582B $0.096B
Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It also offer process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. Avid Bioservices Inc., formerly known as Peregrine Pharmaceuticals Inc., is based in TUSTIN, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00